News | November 21, 2024
Siegfried opens global R&D Center for Drug Substances in Switzerland
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated
